Brought to you by 
Centessa Pharmaceuticals Nets $353M in Nasdaq IPO of ADSs
01 Feb 2022
Executive Summary
Asset centric start-up Centessa Pharmaceuticals Ltd. netted $353Med its initial public offering of 19M American Depositary Shares (ADSs; each represents one ordinary share and includes full exercise of the overallotment) at $20 per ADS (the high end of its anticipated $18-20 range) on the Nasdaq Global Market. It originally planned to offer 15M shares. Following the close of the IPO, the company changed its name to Centessa Pharmaceuticals plc.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Centessa Pharmaceuticals Nets $353M in Nasdaq IPO of ADSs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice